GPT and metabolic dysfunction-associated steatotic liver disease: ALT and AST are commonly used to assess whether hepatocytes are damaged or not (Valizadeh et al., 2011), and can be used as biomarkers to diagnose the progression of MASLD (Zelber-Sagi et al., 2022).